• Je něco špatně v tomto záznamu ?

Hsp90 Levels in Idiopathic Inflammatory Myopathies and Their Association With Muscle Involvement and Disease Activity: A Cross-Sectional and Longitudinal Study

H. Štorkánová, S. Oreská, M. Špiritović, B. Heřmánková, K. Bubová, O. Kryštůfková, H. Mann, M. Komarc, K. Slabý, K. Pavelka, L. Šenolt, J. Zámečník, J. Vencovský, M. Tomčík

. 2022 ; 13 (-) : 811045. [pub] 20220128

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22011243

Background: Heat shock proteins (Hsp) are chaperones playing essential roles in skeletal muscle physiology, adaptation to exercise or stress, and activation of inflammatory cells. We aimed to assess Hsp90 in patients with idiopathic inflammatory myopathies (IIM) and its association with IIM-related features. Methods: Hsp90 plasma levels were analyzed in a cross-sectional cohort (277 IIM patients and 157 healthy controls [HC]) and two longitudinal cohorts to assess the effect of standard-of-care pharmacotherapy (n=39 in early disease and n=23 in established disease). Hsp90 and selected cytokines/chemokines were measured by commercially available ELISA and human Cytokine 27-plex Assay. Results: Hsp90 plasma levels were increased in IIM patients compared to HC (median [IQR]: 20.2 [14.3-40.1] vs 9.8 [7.5-13.8] ng/mL, p<0.0001). Elevated Hsp90 was found in IIM patients with pulmonary, cardiac, esophageal, and skeletal muscle involvement, with higher disease activity or damage, and with elevated muscle enzymes and crucial cytokines/chemokines involved in the pathogenesis of myositis (p<0.05 for all). Plasma Hsp90 decreased upon pharmacological treatment in both patients with early and established disease. Notably, Hsp90 plasma levels were slightly superior to traditional biomarkers, such as C-reactive protein and creatine kinase, in differentiating IIM from HC, and IIM patients with cardiac involvement and interstitial lung disease from those without these manifestations. Conclusions: Hsp90 is increased systemically in patients with IIM. Plasma Hsp90 could become an attractive soluble biomarker of disease activity and damage and a potential predictor of treatment response in IIM.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011243
003      
CZ-PrNML
005      
20220506131113.0
007      
ta
008      
220425s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fimmu.2022.811045 $2 doi
035    __
$a (PubMed)35154129
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Štorkánová, Hana $u Institute of Rheumatology, Prague, Czechia $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czechia
245    10
$a Hsp90 Levels in Idiopathic Inflammatory Myopathies and Their Association With Muscle Involvement and Disease Activity: A Cross-Sectional and Longitudinal Study / $c H. Štorkánová, S. Oreská, M. Špiritović, B. Heřmánková, K. Bubová, O. Kryštůfková, H. Mann, M. Komarc, K. Slabý, K. Pavelka, L. Šenolt, J. Zámečník, J. Vencovský, M. Tomčík
520    9_
$a Background: Heat shock proteins (Hsp) are chaperones playing essential roles in skeletal muscle physiology, adaptation to exercise or stress, and activation of inflammatory cells. We aimed to assess Hsp90 in patients with idiopathic inflammatory myopathies (IIM) and its association with IIM-related features. Methods: Hsp90 plasma levels were analyzed in a cross-sectional cohort (277 IIM patients and 157 healthy controls [HC]) and two longitudinal cohorts to assess the effect of standard-of-care pharmacotherapy (n=39 in early disease and n=23 in established disease). Hsp90 and selected cytokines/chemokines were measured by commercially available ELISA and human Cytokine 27-plex Assay. Results: Hsp90 plasma levels were increased in IIM patients compared to HC (median [IQR]: 20.2 [14.3-40.1] vs 9.8 [7.5-13.8] ng/mL, p<0.0001). Elevated Hsp90 was found in IIM patients with pulmonary, cardiac, esophageal, and skeletal muscle involvement, with higher disease activity or damage, and with elevated muscle enzymes and crucial cytokines/chemokines involved in the pathogenesis of myositis (p<0.05 for all). Plasma Hsp90 decreased upon pharmacological treatment in both patients with early and established disease. Notably, Hsp90 plasma levels were slightly superior to traditional biomarkers, such as C-reactive protein and creatine kinase, in differentiating IIM from HC, and IIM patients with cardiac involvement and interstitial lung disease from those without these manifestations. Conclusions: Hsp90 is increased systemically in patients with IIM. Plasma Hsp90 could become an attractive soluble biomarker of disease activity and damage and a potential predictor of treatment response in IIM.
650    _2
$a dospělí $7 D000328
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a průřezové studie $7 D003430
650    _2
$a cytokiny $x krev $7 D016207
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a proteiny tepelného šoku HSP90 $x krev $7 D018841
650    _2
$a lidé $7 D006801
650    _2
$a longitudinální studie $7 D008137
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a kosterní svaly $x patologie $7 D018482
650    _2
$a myozitida $x krev $x diagnóza $7 D009220
650    _2
$a regresní analýza $7 D012044
650    _2
$a stupeň závažnosti nemoci $7 D012720
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Oreská, Sabína $u Institute of Rheumatology, Prague, Czechia $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Špiritović, Maja $u Institute of Rheumatology, Prague, Czechia $u Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czechia
700    1_
$a Heřmánková, Barbora $u Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czechia
700    1_
$a Bubová, Kristýna $u Institute of Rheumatology, Prague, Czechia $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Kryštůfková, Olga $u Institute of Rheumatology, Prague, Czechia $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Mann, Heřman $u Institute of Rheumatology, Prague, Czechia $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Komarc, Martin $u Department of Methodology, Faculty of Physical Education and Sport, Charles University, Prague, Czechia
700    1_
$a Slabý, Kryštof $u Department of Rehabilitation and Sports Medicine, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czechia
700    1_
$a Pavelka, Karel $u Institute of Rheumatology, Prague, Czechia $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Šenolt, Ladislav $u Institute of Rheumatology, Prague, Czechia $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Zámečník, Josef $u Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czechia
700    1_
$a Vencovský, Jiří $u Institute of Rheumatology, Prague, Czechia $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Tomčík, Michal $u Institute of Rheumatology, Prague, Czechia $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czechia
773    0_
$w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 13, č. - (2022), s. 811045
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35154129 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506131105 $b ABA008
999    __
$a ok $b bmc $g 1789042 $s 1162441
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 13 $c - $d 811045 $e 20220128 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace